Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

Inclusion Criteria: * age: ≥ 70 years inclusive at Visit 1. * patients with a confirmed diagnosis of T2DM * HbA1c of ≥ 7% and ≤10.0% by central laboratory at Visit 1 and assessed by the investigator to be inadequately controlled * body mass index (BMI) in the range of 19-45kg/m2 Exclusion Criteria: * FPG ≥ 270 mg/dL (≥ 15.0 mmol/L) * previous or current participation in any vildagliptin clinical study. * history of hypersensitivity to DPP-4 inhibitors. * concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study. * donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period Other protocol-defined inclusion/exclusion criteria may apply